Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of “Buy” by Brokerages

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) has been assigned an average rating of “Buy” from the eight brokerages that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $37.8333.

Several brokerages have weighed in on EYPT. Guggenheim reaffirmed a “buy” rating and issued a $68.00 price objective on shares of Eyepoint Pharmaceuticals in a report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Tuesday, April 21st. Chardan Capital boosted their price target on Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. HC Wainwright boosted their price target on Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Finally, Citigroup boosted their price target on Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Monday, March 9th.

Eyepoint Pharmaceuticals Price Performance

Shares of NASDAQ EYPT opened at $13.71 on Friday. The stock has a market capitalization of $1.15 billion, a PE ratio of -3.92 and a beta of 1.72. The business has a fifty day moving average price of $13.25 and a two-hundred day moving average price of $14.60. Eyepoint Pharmaceuticals has a fifty-two week low of $8.95 and a fifty-two week high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.79) by ($0.20). The company had revenue of $0.70 million during the quarter, compared to analyst estimates of $0.35 million. Eyepoint Pharmaceuticals had a negative net margin of 3,566.63% and a negative return on equity of 110.54%. On average, equities analysts expect that Eyepoint Pharmaceuticals will post -3.09 EPS for the current year.

Insider Activity at Eyepoint Pharmaceuticals

In other news, insider Ramiro Ribeiro sold 2,437 shares of the business’s stock in a transaction on Friday, April 17th. The stock was sold at an average price of $15.00, for a total transaction of $36,555.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 5.13% of the company’s stock.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

Institutional investors have recently modified their holdings of the business. KBC Group NV acquired a new position in shares of Eyepoint Pharmaceuticals during the 1st quarter worth $29,000. Mirae Asset Global Investments Co. Ltd. grew its position in Eyepoint Pharmaceuticals by 51.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock worth $74,000 after acquiring an additional 1,358 shares during the last quarter. California State Teachers Retirement System grew its position in Eyepoint Pharmaceuticals by 20.6% during the 4th quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock worth $85,000 after acquiring an additional 794 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in Eyepoint Pharmaceuticals during the 3rd quarter worth $76,000. Finally, Persistent Asset Partners Ltd bought a new stake in Eyepoint Pharmaceuticals during the 4th quarter worth $98,000. Institutional investors and hedge funds own 99.41% of the company’s stock.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.